Leticia Cano, J Mol Biomark Diagn 2013, 4:3
http://dx.doi.org/10.4172/2155-9929.S1.017

OMICS Group Conferences
Accelerating Scientific Discovery

4th International Conference on
Biomarkers & Clinical Research
July 15-17, 2013 Courtyard by Marriott Philadelphia Downtown, USA

Biomarker discovery using proteins identified across disease

Leticia Cano
Biomarker Profile Corporation, USA

Biomarker discovery is a difficult series of experiments due to the number of different molecules in clinical samples, the wide dynamic range of these molecules, their fluctuations and modifications. Often, it is difficult to determine which molecules should be selected as biomarker candidates for a particular purpose. Biomarkers can be used as indicators of disease, disease progression, and response to therapy or complications. Often disease is studied in comparison to healthy controls. However, we find that the comparison of biomarkers across different disease yields a different set of candidates than if the disease were studied in isolation. In this talk, we will present our discovery strategy and discuss the development of a biomarker database to aid in biomarker selection.

Biography

Leticia Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her Ph.D. dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis Systemic Lupus Erythematosis. As founder and president of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery.

leticiacano@biomarkerprofiles.com